Regeneron CEO: Our Drug Is Not Manufactured Using Fetal Cells

By Melanie Arter | October 12, 2020 | 4:57pm EDT
President Donald Trump taking his mask off before speaking at a rally from the South Portico of the White House in Washington, DC on October 10, 2020 shows. - Trump spoke publicly for the first time since testing positive for Covid-19, as he prepares a rapid return to the campaign trail just three weeks before the election. (Photo by MANDEL NGAN/AFP via Getty Images)
President Donald Trump taking his mask off before speaking at a rally from the South Portico of the White House in Washington, DC on October 10, 2020 shows. (Photo by MANDEL NGAN/AFP via Getty Images)

(CNSNews.com) – Regeneron founder, president, and CEO Leonard Schleifer told CBS’s “Face the Nation” on Sunday that the experimental treatment his company manufactures, which was used to treat President Donald Trump for COVID-19, was not manufactured using fetal stem cells.

“I want to ask you something specific to how your drug was developed. According to your company, the antibodies in it were developed using cells that were derived from fetal tissue, a cell line known as 293T. Those were harvested from the kidney tissue of an aborted fetus,” host Margaret Brennan said.


“There are also vaccine makers using this cell line, but the Trump administration last year has suspended federal funding for research projects that involve fetal tissue from abortions. Should the resident and the administration reconsider it, given that this breakthrough was possible using those kind of cells?” she asked.
 
“Let me be very clear, our drug is not manufactured using fetal cells. That's not the way you make the product,” Schleifer said.

 

BRENNAN: I understand that, developed, but not--

SCHLEIFER: It's just-- so let's not-- We shouldn't exaggerate the situation. This--

BRENNAN: I'm not. I'm reading what your company said, which was it was developed using it.

SCHLEIFER: Yeah. I wasn't suggesting you are. I'm just saying we as a society - and it's not used to manufacture the product. It was-- it's a standard cell line that was derived over 50 years ago, and so it's used as a research tool. Where that research should be done, that's a good debate to have, but it's probably kind of the debate we need to have right now.

BRENNAN: Okay. Who should be getting this drug in terms of how you think it should be used? If-- is it a prophylactic? Should it be given to diabetics, asthmatics, pregnant people?

SCHLEIFER: Right. Those are great questions, Margaret. It can be used, we think, as a prophylactic. We're doing a trial to see whether or not if you live in the household of somebody who's got it, whether it would stop you from getting it, and that would be very important evidence that we hope to get in the not too distant future. Then we might think about if somebody in the nursing home gets it. We-- maybe--we can treat the other people in the nursing home. If people who are very sick are exposed to people, people who don't have good immune systems.

CNSNews Reader,

The media are hard at work weaving a web of confusion, misinformation, and conspiracy surrounding the COVID-19 pandemic.

CNSNews covers the stories that the liberal media are afraid to touch. It drives the national debate through real, honest journalism—not by misrepresenting or ignoring the facts.

CNSNews has emerged as the conservative media’s lynchpin for original reporting, investigative reporting, and breaking news. We are part of the only organization purely dedicated to this critical mission and we need your help to fuel this fight.

Donate today to help CNSNews continue to report on topics that the liberal media refuse to touch. $25 a month goes a long way in the fight for a free and fair media.

And now, thanks to the Coronavirus Aid, Relief, and Economic Security (CARES) Act, you can make up to a $300 gift to the 501(c)(3) non-profit organization of your choice and use it as a tax deduction on your 2020 taxes, even if you take the standard deduction on your returns.

— The CNSNews Team

DONATE

Connect

Sign up for our CNSNews Daily Newsletter to receive the latest news.